Evidence map›Paper›PMID 36247976›Full record

ArticleFrontiers in epidemiology2022

Metagenomic Pathogen Sequencing in Resource-Scarce Settings: Lessons Learned and the Road Ahead.

Christina Yek, Andrea R Pacheco, Manu Vanaerschot, Jennifer A Bohl, Elizabeth Fahsbender, Andrés Aranda-Díaz, Sreyngim Lay, Sophana Chea, Meng Heng Oum, Chanthap Lon and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Frontiers in epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Veterinary sciences · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Christina YekDepartment of Critical Care Medicine, National Institutes H(of Health Clinical Center, Bethesda, Maryland, USA.
Andrea R PachecoInternational Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Manu VanaerschotChan Zuckerberg Biohub, San Francisco, California, USA.
Jennifer A BohlVaccine Immunology Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Elizabeth FahsbenderChan Zuckerberg Biohub, San Francisco, California, USA.
Andrés Aranda-DíazChan Zuckerberg Biohub, San Francisco, California, USA.
Sreyngim LayInternational Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Sophana CheaInternational Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Meng Heng OumInternational Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Chanthap LonInternational Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Cristina M TatoChan Zuckerberg Biohub, San Francisco, California, USA.
Jessica E ManningLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.
Chan Zuckerberg Initiative (United States) · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health Clinical Center · US

Funding

International Research in Cambodia: Tropical Medicine and Vector Research ZIAAI001066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI YEK, CHRISTINA · 2009 to 2025
$10.8M
Intramural NIH HHS ZIA AI001066
6 · The paper itself

Abstract

Metagenomic next-generation sequencing (mNGS) is the process of sequencing all genetic material in a biological sample. The technique is growing in popularity with myriad applications including outbreak investigation, biosurveillance, and pathogen detection in clinical samples. However, mNGS programs are costly to build and maintain, and additional obstacles faced by low- and middle-income countries (LMICs) may further widen global inequities in mNGS capacity. Over the past two decades, several important infectious disease outbreaks have highlighted the importance of establishing widespread sequencing capacity to support rapid disease detection and containment at the source. Using lessons learned from the COVID-19 pandemic, LMICs can leverage current momentum to design and build sustainable mNGS programs, which would form part of a global surveillance network crucial to the elimination of infectious diseases.

Indexed as

biosurveillanceCOVID-19LMICMetagenomicsnext-generation sequencing

Identifiers

PMID36247976
PMCPMC9558322
OpenAlexW4291383229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.